top of page

Revised objectives for Polymer Factory Sweden AB (publ)

The Board of Directors of Polymer Factory Sweden AB (publ) (“Polymer Factory” or the “Company”) has today, November 7, 2022, adopted revised objectives for the Company. To promote continued value creation, the Company has set out new internal and external financial and non-financial objectives. Polymer Factory’s main objective is to meet the increasing demand from the market by preparing the Company and continue working towards securing new partnership agreements with Big Pharma, MedTech, or BioTech companies with a focus on dendritic amplifiers for product enhancement. Connected to this, the Board of Directors has set out an updated financial objective to have a minimum of 25 percent sales growth annually by 2025.

Since its listing on Spotlight Stock Market in 2021, Polymer Factory has come a long way in strengthening the organization and increasing sales. The Company not only closed the year 2021 with increased revenues, but also launched its new product segment BowtieD®. During the first half of 2022, Polymer Factory has primarily focused on expanding the team and deepening the relationship with its customers, while continuing to engage new leads. On the product development side, Polymer Factory progressed with the development of Dendritic Nanogel (DNG) as a future competitor to liposome carriers, and the expansion of SpheriCal®. Through these strategic actions Polymer Factory has more clearly become a key player that through our different business areas for dendritic materials is active throughout the global market. The Company has an established business infrastructure with the possibility of global up-scale of sales, and with large margins on current sales. Existing partnerships and collaborations also create favorable conditions for establishing new partnerships with multinational corporations.

Find the full press release, including financial and non-financial objectives, here:

Press release Nov 7
Download PDF • 230KB


bottom of page